Comparative Bioavailability of Risperidone

Summary

This is an open-label, one sequence study to evaluate the steady-state comparative bioavailability of 100 mg Risperidone ISM® injectable every 4 weeks compared to once daily 4 mg oral risperidone in subjects with schizophrenia stabilized on oral risperidone treatment.

Timeline

Start

2018-07-09

Primary completion

2019-03-23

Completion

2019-04-06

Drugs

Indications